AstraZeneca is a global innovation driven biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines.
Science can change our vision of the world and how we deal with the diseases that affect us. The future of treatment for many of today’s diseases lies in uncovering disease mechanisms that are newly emerging or are still to be discovered. Science challenges us to push the limits of what is possible. This is why we put science at the centre of everything we do.
At AstraZeneca every one of our employees makes a difference to patient lives every day. We are inspired by the things that seem impossible and stimulate continued creativity throughout our organisation, maintaining a culture in which our people feel valued for their ideas and contributions. Ideas that can make a difference in all aspects of our business and to healthcare in Africa.
Our regional and country offices serve as a hub of communication between our office-based staff and more than half the company's employees that are directly involved in the promotion of our medicines to Healthcare Professionals throughout our markets in our African Cluster.
AstraZeneca has been working to deliver the best value to patients in Africa for over 25 years. Our vision is to transform the lives of patients, ensuring all Africans have access to our innovative medicines.
Northdowns Office Park
17 Georgian Crescent West
BRYANSTON – 2021
Johannesburg – South Africa
Tel:+27 (0) 11 797 6000
Fax: +27 (0) 86 640 1463
P.O Box 10107, Nairobi, Kenya
Tel:+254 20 2714812
Our Senior management team
Barbara Nel Country President: African Cluster
Alexander Lygin CFO: African Cluster
Dr Khomotso Mashilane Medical Director: African Cluster
Ursula Du Preez Primary Care Strategy Director: African Cluster
Fatima De Castro Business Unit Director Oncology: African Cluster
Dr Sylvia Vito Project Management Officer: Africa Acceleration Programme
Smita Ramouthar Human Resources Director: African Cluster
Arpit Bansal Country Director: Sub Saharan Africa
Adélaïde Ehouman Country Director: French Speaking Africa
Phumlani Mancapha Primary Care Sales Director: South Africa
Ruth Field Market Access and Government Affairs Director: South Africa
Dr Kennedy Njau Government Affairs Director: Sub Saharan Africa
Carlo Budree Head of IT & Digital: African Cluster
Reshma Singh Compliance Senior Manager: African Cluster
OUR THERAPEUTIC AREAS
Unlocking the power of what science can do.
We market medicines that are designed to improve the health and quality of life of patients, focusing on 3 main therapy areas: Respiratory; Cardiovascular, Renal and Metabolism (CVRM) with newer treatments in Type 2 Diabetes Mellitus being our core strength; and Oncology with targeted and immune-oncology therapies being the future portfolio in cancer management.
At AstraZeneca, Cardio-Vascular, Renal and metabolism (CVRM) is one of our main therapy areas because science continues to uncover commonalities between cardiovascular, renal and metabolic diseases. With this knowledge, we are daring to do things differently by shifting focus from treating patients with a single disease, to addressing overlapping disease areas and risk factors. This is why we have created a distinct approach to care for Cardiovascular, Renal and Metabolic diseases – CaReMe. This new approach gives us the chance to save vital time and valuable healthcare resources, and most importantly improve patient lives.
Diabetes is a disease of epidemic scale and an important strategic focus for AstraZeneca. With reportedly over 19.4 million adults living with diabetes in Africa in 2019 (IDF Atlas 9th edition), we are focused on redefining the Type 2 diabetes treatment approach and harnessing complementary mechanisms of action, as well as cardiovascular outcomes benefits.
As facilitators of the CaReMe approach, we make it our responsibility to help Healthcare Professionals connect the dots, evolve their clinical practice and provide complete, potentially life-saving care for CVRM patients. Our priority is to empower Healthcare Professionals to diagnose and treat earlier in the course of the disease. It is through partnering with all healthcare stakeholders that we can protect patients against heart and renal failure, improve health and save the lives of patients in Africa living with these diseases.
For more than 40 years we have developed drugs to combat cancer, many of which have increased survival rates for patients around the world. We aim to advance the science of oncology with a combination-focused pipeline set to address the unmet clinical needs in a host of cancers. Our vision is to redefine the cancer treatment paradigm in Africa, with our primary focus on prostate cancer, breast cancer and lung cancer.
In Kenya we are collaborating with the Ministry of Health (MoH) in the roll out of the new Oncology treatment protocols to Healthcare Professionals across the country. The development and dissemination of the treatment protocols will help to standardize practice and ensure universal access to quality cancer care at the MoH facilities.
In South Africa AstraZeneca has a proven track record of working collaboratively and successfully with the Government and health partners to bring medicines for chronic conditions to South African patients in a timely manner and securing expanded access to these medicines via our Phakamisa programme, with a strong focus on Breast and Prostate Cancer.
Our goal is to establish a leading position in Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Africa. We aim to bring scientific education to the medical community, value to the patient, help redefine standards of care and raise awareness of the ongoing unmet medical needs in Asthma and COPD in Africa. We host a variety of forums and meetings annually, highly regarded by the scientific community and attended by prominent respiratory specialists in South Africa and Africa.
AstraZeneca will continue to optimise clinical practice in Africa through a range of medications including differentiated inhaled therapies, novel combinations and devices for asthma and COPD to improve choice and outcomes for patients. Our inhaled treatments are the foundation of our respiratory portfolio in Africa and core to our business.
The respiratory clinical community laid down a challenge to improve asthma care globally in the 2018 Lancet Commission. AstraZeneca shares the belief that there should be zero tolerance for preventable asthma attacks. People living with asthma should have the ability to lead normal lives and deserve the best care. While we recognise that these are long-term goals, we are unwavering in our commitment to improve care for asthma patients across Africa.
WORKING WITH OUR HEALTHCARE PROFESSIONALS IN AFRICA
We engage extensively with our Healthcare Professionals (HCPs) from participation in clinical trials and as part of our sales and marketing work, ensuring that clinicians have the best access to information about our products in order to make appropriate treatment decisions, delivering better patient care.
As part of our collaboration and engagement with HCPs we support the development and delivery of medical education services.
OUR INVESTMENT IN CONTINUOUS MEDICAL EDUCATION THROUGH THE APPLICATION OF DIVERSE PLATFORMS
- We have a strong scientific team of qualified Medical Doctors and Specialists providing key scientific support, across our key Therapeutic Areas, to HCPs and our AstraZeneca teams.
- We collaborate with medical societies to increase awareness of global management guidelines. We continually explore additional areas for collaboration with medical and pharma societies, with the aim of supporting the education of Healthcare Professionals (HCPs).
- We have worked extensively to bring some of the best educational resources and key experts to Africa to expand scientific education programmes and knowledge sharing amongst HCPs.
- The ePD platform in South Africa and Greatminds platform in Sub Sahara, provides doctors access to current, relevant content with international and local speakers. An interactive learning experience utilising technology that offers a solution that best suits doctors’ needs and time.
- Our AZEngage platform is our online Continuous Professional Development and Training platform for HCPs. The site provides an easy-access platform to view current and accredited CPD videos from the location of choice, expanding our scientific information offering and providing the latest information on medical journal publications.
- AstraZeneca Africa utilises live Video conferencing platforms to host international speakers, bringing international knowledge to the region and combining this with local expertise.
- Our AZCVRM.co.za HCP portal offers rich content on Cardiovascular Renal and Metabolic (CVRM) diseases, for South African Health Care Professionals.
- AZBrands.co.za HCP portal offers our Health Care Professionals product related information.
PARTNERING WITH GOVERNMENTS AND POLICY MAKERS IN AFRICA
Our Continent’s future social and economic development will depend on an equitable and inclusive healthcare system that is able to respond to the healthcare needs of all Africans. At AstraZeneca we are committed to working with governments, policy makers and regulatory bodies across our markets to ensure that patients in Africa have access to innovative medicines when they need them.
We want our treatments to improve the lives of as many people as possible. This goal calls for us to actively participate in discussions with governments and healthcare stakeholders on healthcare reform to deliver a sustainable solution that ensures patients encounter fewer barriers to treatment.
SUPPORTING OUR PATIENTS AND COMMUNITY
At AstraZeneca we work together across global boundaries to make an impact and find answers to challenges. In Africa we consider our responsibility to our patients and our community as an integral part of what we do. When we see an opportunity for change we seize it and make it happen, because an opportunity no matter how small can be the start of something big.
Our commitment to improve health outcomes for African patients extends far beyond our medicines. We offer programmes that advance patient health and access along the care continuum and provide reliable support networks.
Programmes active in our African Cluster
Healthy Heart Africa
Developed by AstraZeneca and implemented across Africa in collaboration with African Governments and Non-Governmental Organizations (NGOs), Healthy Heart Africa (HHA) is designed to contribute to the prevention and control of hypertension and decreasing the burden of cardiovascular disease (CVD) across Africa. Currently present in Kenya, Ethiopia, Tanzania and Ghana, the programme supports sustainable models by working with local health systems. Each model works independently with partners in the country of implementation to address different health challenges and health environments, with the aim of providing a sustainable means of fighting hypertension in Africa.
Healthy Heart Africa aspires to reach 10 million hypertensive patients across Sub-Saharan Africa by 2025, supporting the World Health Organisation’s global hypertension target (25% reduction by 2025). The programme was launched in October 2014 in collaboration with the Kenyan Ministry of Health and a group of well-respected implementing partners. We have developed strong relationships with local health partners, governments and Ministries of Health in the region, with Memorandums of Understanding entered into with the Ministries of Health in Kenya, Ethiopia, Tanzania and Ghana.
In support of the United Nations targets to reduce the risk of premature death from NCDs along with the Pan-African Society of Cardiology (PASCAR) ‘Roadmap’ to reduce heart disease and stroke2, HHA aspires to reach 10 million people with elevated blood pressure by 2025, working together with local and global partners to:
- Increase awareness and educate around lifestyle choice and CVD risk factors
- Train providers and drive care to lower levels of the healthcare system
- Facilitate access to low cost, high quality branded anti-hypertensives
Healthy heart Africa has also embarked on an innovative public-private partnership with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to tackle the burden of HIV and hypertension in Africa. At the foundation of the partnership is a shared commitment to reaching those outside of the traditional entry points to care, with a particular emphasis on men. More information on Healthy Heart Africa in Kenya, Ethiopia Tanzania and Ghana can be found here.
R. L. Sacco et al. The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke. Circulation. 2016, 11:e674-e690. Available at: https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000395 Last accessed November 2019.
2 A. Dzudie et al. PASCAR Roadmap on Hypertension. Roadmap to achieve 25% hypertension control in Africa by 2025. Cardiovascular Journal of Africa. 2017. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642030/pdf/cvja-28-262.pdf Last accessed November 2019.
Young Health Programme
Our award-winning AstraZeneca Young Health Programme has a unique focus on young people and primary prevention of the most common non-communicable diseases (NCDs). Working in partnership with global and local organisations, the Young Health Programme works to positively impact the health of adolescents through research, evidence generation, advocacy for change and on-the-ground programmes. The Young Health Programme was launched in Kenya in partnership with Plan International in 2016 and aims to contribute to improved health and gender equality of 82 000 young people, aged 10-24, in Kibera, Kenya, over 5 years. More information about the Young Health Programme can be found here.
Step Up! Global Grants Programme
Through the Step Up! Global Grants Programme AstraZeneca extends the reach and impact of its Young Health Programme to support non-profit organisations that are working in the area of youth health and disease prevention. Since the launch of the programme in 2018 thirteen grants have been awarded to organisations with a charitable purpose across the African Cluster. More information on the Step Up! grants programme and our Step Up! grantees and their projects can be found here.
NCD National Screening campaign
Non-Communicable Diseases (NCD) National Screening campaign in partnership with the Department of Health
AstraZeneca is currently working in partnership with the National Department of Health to implement a national screening programme for Non-Communicable Diseases. The national screening programme will empower and equip community health outreach workers with the right knowledge and tools to complete comprehensive health screening at community household level using digital devices. The digital device automatically connects the community intervention with health systems and other government sectors ensuring the availability of real-time data. Based on data collected, it is possible to guide the individual towards either the health promotion and disease prevention activities or to enter the health system into the correct level of care for appropriate interventions, in the shortest period and most efficient manner.
Phakamisa is AstraZeneca’s access to healthcare initiative in South Africa aimed at improving the health outcomes for patients. The broader goal of the Programme is to lessen the burden of non-communicable diseases on South Africa’s public healthcare system.
Phakamisa empowers patients, community healthcare outreach workers and Healthcare Professionals through capacity building, education and awareness. The Programme specifically addresses early detection of disease; promotion of primary prevention; and access to care.
Phakamisa, which means ‘to uplift’ in Zulu, has run a successful awareness for Breast Cancer Programme to patients utilizing Navigators. Since its inception in 2011, the Programme has reached thousands of people throughout South Africa.
A WORLD CLASS RESEARCH AND DEVELOPMENT PLAYER
Clinical Research & Development
AstraZeneca Africa Cluster has proven its willingness to play a significant role in international R&D through a strong investment in clinical studies, across therapeutic areas, with added value for local doctors and patients.
We have had significant involvement in the rich pipeline of candidate drugs emerging from R&D sites. High quality work with specialists and primary care physicians in South Africa over the past years has resulted in a steady increase of trial work being awarded to the Clinical Research Department in South Africa, which attained key country status in 2000.
Our focus is on adding value, not only to our global company’s research and development programme, but also to the society within which we operate; the institutions and academic centres of medical excellence with whom we have partnered in our work; and finally to the patients whom we serve. South Africa has and continues to participate in many key AstraZeneca projects over all therapeutic areas and is experienced in conducting phase I-IV trials. Currently, AstraZeneca South Africa is involved in 21 trials spanning different therapeutic areas and is working with 152 clinical centres (March 2020). We also conduct CRO led studies locally.
In Kenya AZ is conducting the sickle cell disease in paediatrics study, the first R&D phase III trial initiated in Kenya for sickle cell disease in paediatrics. This research commitment in a population where non-communicable diseases are exponentially increasing with minimal intervention, supports our bold ambition of improving lives.
Critically aware of the increasing health challenges in Africa and the need for quality scientific data to properly manage and treat potentially life-threatening illnesses, we participate in global research studies in our key markets strengthening Africa’s medical research capability to solve local challenges.
Global research studies in our markets:
DISCOVER REGISTRY: A global real-world evidence registry of patients with type 2 diabetes mellitus that is moving the frontiers of Medicine.
DISCOVER STUDY: A global observational study of patients with type 2 diabetes mellitus who are starting second-line glucose-lowering therapy.
COPVAR: A cross-sectional study of patients with severe COPD to assess patient perception of symptom variability in Middle East & Africa countries.
DECLARE: DECLARE (Dapagliflozin Effect on Cardiovascular Events)-TIMI 58 a randomised, double-blinded, placebo-controlled, multi-centre trial designed to evaluate the effect of Forxiga compared with placebo on CV outcomes in adults with T2D at risk of CV events, including patients with multiple CV risk factors or established CV disease.
SABINA: A multi-centre observational study on the prescription patterns of short-acting Beta-2 agonists, SABA, and its implications on asthma control.
HESTIA STUDIES: A study to evaluate the effect of Ticagrelor in reducing the rate of Vaso-Occlusive Crises in Paediatric patients with Sickle Cell Disease.
Scientific research studies conducted in collaboration with external stakeholders:
A prospective, longitudinal, epidemiological study to categorise and electronically capture data of all respiratory patients attending the outpatients clinic at the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in South Africa. The study will aim to electronically capture data as well as attempt to standardise the clinical assessment and therapeutic interventions on all patients attending the various pulmonology outpatient clinics at the CMJAH. The study will also introduce various tools validated for assessment of the different pulmonary disease entities and use these objective scoring systems to assess patient severity and response to therapy.
Lung function predictive equations for healthy South African children and adults: The Paediatric and Adult African Spirometry Working Group. This study will aim to determine the normal reference equations for spirometry in South African adults and children.
WORKING AT ASTRAZENECA
At AstraZeneca, we’re driven by innovation and our commitment to make a real-life difference in patients’ lives. That difference starts with you. We need people like you who share our passion for science and determination to meet patients’ needs around the world.
From medical science to sales & marketing, we’re on a mission to turn ideas into life-changing medicines. If you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us.
Good governance is crucial to ensuring we are well managed and can deliver our strategic priorities. Our Code of Ethics sets out the ethical standards we expect of everyone who works at AstraZeneca and, along with our global policies, how these are to be translated into consistent actions worldwide.
PATIENT SAFETY AND ADVERSE EVENT REPORTING
The safety of patients who take our medicines is of fundamental importance to AstraZeneca. We continuously work to identify and minimise the risks and maximise the benefits of each of our medicines.
This information is used by the company to further enhance our understanding of the safety profile of our medicines and ensure we can treat patients effectively.
If you would like to report an adverse event for an AstraZeneca product, please contact AstraZeneca Safety Managers:
SOUTH AFRICA CONTACT DETAILS
Phone: +27 11 797 6193 / 6000
Fax: +27 11 797 6019
Out of hours emergency contact details
South Africa +27 72 758 7638
SUB SAHARAN AFRICA CONTACT DETAILS
Phone: +27 11 797 6243 / 6000
Out of hours emergency contact details
Angola +244 94 359 5906
Ghana +233 50 130 9984
Kenya +254 70 294 7265
Nigeria +234 803 979 0404
Uganda +256 75 030 8830
Sub Saharan Africa +27 79 798 4548
AstraZeneca recommends the use of its products in accordance with the approved local prescribing information. Please refer to the approved local package insert full prescribing information for approved product labelling and important safety information. Should you wish to contact AstraZeneca Medical Information directly about medical enquiries relating to AstraZeneca products, please submit a request to SSA.MEAMedInfo@astrazeneca.com (SSA) or SA.MEAMedInfo@astrazeneca.com (South Africa).
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
Science compels us to push the boundaries of what is possible. We trust in the potential of ideas and pursue them, alone and with others, until we have transformed the treatment of disease.